Since its first report in Wuhan, China, in December 2019, the novel pandemic COVID‐19, caused by SARS‐CoV‐2 virus, has rampaged throughout the world.1 People with asthma and allergies are usually at greater risk of more severe outcomes with virus infections. However, recent reports have accumulated evidences that the prevalence of allergic diseases and asthma in patients with COVID‐19 is lower than expected among other comorbidities and risk factors of the severe form of COVID‐19 (Appendix S1 for additional reference 1‐3). Why are then allergic diseases and asthma underrepresented as co‐morbid risk factors in patients with COVID‐19? Is this a sampling bias in the currently published clinical reports or is there a real discrepancy in the prevalence of asthma among COVID‐19‐infected patients that may glean a light for us to fight this pandemic? Here, we hypothesize the plausible mechanisms in asthmatics based on available publications (Appendix S1) that may have effects in determining their susceptibility to and disease severity with SARS‐CoV‐2 infection.
